Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $52.50 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Puma Biotechnology Price Performance

Puma Biotechnology stock opened at $2.86 on Wednesday. The company has a market capitalization of $140.39 million, a price-to-earnings ratio of 5.96 and a beta of 1.09. The stock’s 50 day moving average is $3.00 and its 200-day moving average is $2.86. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 12 month low of $2.22 and a 12 month high of $7.15.

Insider Activity

In related news, insider Jeffrey Jerome Ludwig sold 9,437 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares of the company’s stock, valued at $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares of the company’s stock, valued at $22,143,473.10. This represents a 0.48 % decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.